<DOC>
	<DOCNO>NCT00145444</DOCNO>
	<brief_summary>This study intend compare novel antipsychotic ziprasidone olanzapine , confirm finding open study -where stable patient receive olanzapine switch ziprasidone- show maintenance clinical effect improvement domains cognitive function 6 week ( Daniel , 1999 ) . Direct comparison two agent well-controlled double-blind fashion allow evaluation effect cognitive function short long-term management patient recent-onset schizophrenia , schizoaffective schizophreniform disorder .</brief_summary>
	<brief_title>Kahn Study ; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis ; A Flexible-Dose , Parallel Group , Double-Blind Study</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Duration illness &lt; 5 year ( accord DSMIV onset first psychotic episode ) ; CGI severity score &gt; 4 ( moderately ill ) maximum exposure antipsychotic treatment = &lt; 16 week . Concurrent treatment antipsychotic agent = &lt; 12 hour prior randomization depot agent period two week one cycle , whichever longer , must occur last administration randomization Treatment antidepressant mood stabilizer = &lt; 7 day randomization MAOIs moclobemide period must = &lt; 2 week fluoxetine = &lt; 5 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>